Fundraising Fox
/Companies
Sign in

Carocellbio

1 known investors

Find your way into Carocellbio

Sign up to see every warm intro you have to Carocellbio

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Carocellbio team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Carocell Bio develops peptide-based anti-inflammatory therapeutics, including its lead peptide JEL0305, that inhibit the intracellular MAPK (p38) inflammatory pathway and are combined with a nanoparticle delivery technology for topical application to the skin. It targets inflammatory conditions such as eczema (atopic dermatitis) and inflammation-related skin ageing.

BiotechDeep TechHealthtech

Founders & leadership

MDMike Davies
Mike DaviesCEO & FounderMike Davies is CEO and founder of Carocell Bio, which develops peptide-based therapeutics combined with nanoparticle delivery technology for inflammatory skin conditions including atopic dermatitis.
AGAshley George
Ashley GeorgeInterim Chairman & Financial DirectorAshley George brings over two decades of global leadership experience across pharmaceuticals, consumer healthcare, and venture-backed startups, including Board-level roles and financial management positions. She holds a visiting professor appointment at University College London and has led digital transformation initiatives and strategic business development across international teams.

Investors · 1

Frequently asked questions

What does Carocellbio do?
Carocell Bio develops peptide-based anti-inflammatory therapeutics, including its lead peptide JEL0305, that inhibit the intracellular MAPK (p38) inflammatory pathway and are combined with a nanoparticle delivery technology for topical application to the skin. It targets inflammatory conditions such as eczema (atopic dermatitis) and inflammation-related skin ageing.
Who founded Carocellbio?
Carocellbio was founded by Mike Davies.
Who are Carocellbio's investors?
Carocellbio's investors include Deepbridge Capital.